Rani Therapeutics Holdings, Inc. Cash Flow Statement
RANI|4 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Rani Therapeutics Holdings, Inc. used $35M in operating cash flow and negative free cash flow of $36M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2022 | FY2021 |
|---|---|---|---|---|
| Net Income | -$30.0M | -$34.0M | -$8.3M | -$8.3M |
| Depreciation & Amortization | $1.0M | $822.0K | $497.0K | $589.0K |
| Operating Cash Flow | -$35.5M | -$51.2M | -$32.2M | -$15.0M |
| Capital Expenditures | $268.0K | $1.2M | $506.0K | $1.2M |
| Free Cash Flow | -$35.8M | -$52.5M | -$32.8M | -$16.2M |
| FCF Margin | -3479.0% | - | -1205.4% | -3497.8% |